|
시장보고서
상품코드
1986344
바이러스 캡시드 개발 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)Viral Capsid Development Market Size, Share & Trends Analysis Report By Type, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
바이러스 캡시드 개발 시장 요약
세계의 바이러스 캡시드 개발 시장 규모는 2025년에 3억 1,430만 달러로 추정되었습니다. 2033년까지 6억 8,450만 달러에 이를 것으로 예측되며, 2026-2033년 CAGR 10.36%로 성장할 전망입니다.
이러한 성장은 유전자 치료에 대한 수요 증가, 바이러스 벡터 연구개발의 활성화, 캡시드 엔지니어링의 발전 등에 의해 주도되고 있지만, 높은 비용과 제조의 복잡성이 확장을 제한할 수 있습니다.
합성생물학과 AI를 활용한 설계의 진보
합성생물학의 발전과 AI를 활용한 설계 기술의 발전으로 개발 정밀도의 향상과 개발 능력의 확대를 통해 바이러스 캡시드 시스템 개발 프로세스가 가속화되고 있습니다. 과학자들은 방향성 진화와 합리적인 단백질 공학을 결합하여 안전성이 향상되고 특정 신체 조직에 도달하는 능력이 뛰어난 맞춤형 유전자 치료제를 전달할 수 있는 맞춤형 벡터를 만들고 있습니다.
방대한 데이터베이스를 분석하는 과정을 통해 인공지능은 최적의 서열을 발견할 수 있어 실험의 필요성을 줄이는 동시에 임상 개발을 촉진하고 우수한 캡시드 엔지니어링 기법에 대한 요구가 높아지고 있습니다. 예를 들어, 2025년 11월 미국 Latus Bio는 AAV 유전자 치료를 위한 AI/ML 전략을 확대했습니다. 이 회사는 광범위한 in vivo 캡시드 데이터 세트를 활용하고 일선 전문가를 영입하여 바이러스 캡시드 개발에서 캡시드 발견, 페이로드 설계 및 표적 전달을 가속화하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 시장 변수, 동향 및 범위
제4장 바이러스 캡시드 개발 시장 : 유형별 분석
제5장 바이러스 캡시드 개발 시장 : 용도별 분석
제6장 바이러스 캡시드 개발 시장 : 최종 용도별 분석
제7장 바이러스 캡시드 개발 시장 : 유형, 용도 및 최종 용도별 지역별 추정 및 동향 분석
제8장 경쟁 구도
LSH 26.05.04Viral Capsid Development Market Summary
The global viral capsid development market size was estimated at USD 314.3 million in 2025 and is projected to reach USD 684.5 million by 2033, growing at a CAGR of 10.36% from 2026 to 2033. Growth is driven by increasing demand for gene therapies, rising viral vector R&D, and advancements in capsid engineering, though high costs and manufacturing complexities may limit expansion.
Advancements in Synthetic Biology & AI-Driven Design
Advancements in synthetic biology, along with AI-powered design advancements, are accelerating the development process of viral capsid systems through enhanced development accuracy and increased developmental capacity. Scientists use directed evolution together with rational protein engineering to create custom vectors that deliver gene therapies with improved safety and better ability to reach specific body tissues.
The process of analyzing extensive databases enables artificial intelligence to discover the best sequences, which decreases the need for experiments while driving clinical development forward and increasing the requirements for superior capsid engineering methods. For instance, in November 2025, in the U.S., Latus Bio expanded its AI/ML strategy for AAV gene therapy, leveraging extensive in vivo capsid datasets and adding leading experts to accelerate capsid discovery, payload design, and targeted delivery in viral capsid development.
Global Viral Capsid Development Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global viral capsid development market report based on the type, application, end-use, and region.
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Adeno-associated Virus (AAV) Capsids
- Adenoviral
- Lentiviral
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Gene Therapy
- Vaccine Development
- Cancer Therapy
- Others
- End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institute
- CROs & CMOs
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Type
- 1.2.2. Application
- 1.2.3. End Use
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.6.1. Primary Research
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Expansion of Gene Therapy Clinical Pipeline
- 3.2.1.2. Increasing Demand for Tissue-Specific and Targeted Delivery Systems
- 3.2.1.3. Growing Outsourcing to Specialized CROs and CDMOs
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Development and Production Costs
- 3.2.2.2. Limited Scalability of Advanced Capsid Platforms
- 3.2.3. Market Opportunity Analysis
- 3.2.3.1. Integration of AI and Machine Learning in Capsid Engineering
- 3.2.3.2. Emerging Applications in Oncology and Rare Diseases
- 3.2.4. Market Challenge Analysis
- 3.2.4.1. Manufacturing Complexity and Process Variability
- 3.2.4.2. Limited Standardization in Capsid Characterization Methods
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
Chapter 4. Viral Capsid Development Market: Type Business Analysis
- 4.1. Type Segment Dashboard
- 4.2. Global Viral Capsid Development Market Type Movement Analysis
- 4.3. Global Viral Capsid Development Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
- 4.4. Adeno-Associated Virus (AAV) Capsids
- 4.4.1. Global Adeno-Associated Virus (AAV) Capsids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Adenoviral
- 4.5.1. Global Adenoviral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Lentiviral
- 4.6.1. Global Lentiviral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Others
- 4.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Viral Capsid Development Market: Application Business Analysis
- 5.1. Application Segment Dashboard
- 5.2. Global Viral Capsid Development Market Application, Movement Analysis
- 5.3. Global Viral Capsid Development Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 5.4. Gene Therapy
- 5.4.1. Global Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Vaccine Development
- 5.5.1. Global Vaccine Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Cancer Therapy
- 5.6.1. Global Cancer Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Others
- 5.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Viral Capsid Development Market: End Use Business Analysis
- 6.1. End Use Segment Dashboard
- 6.2. Global Viral Capsid Development Market End Use Movement Analysis
- 6.3. Global Viral Capsid Development Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 6.4. Pharmaceutical and Biotechnology Companies
- 6.4.1. Global Pharmaceutical and Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Academic and Research Institute
- 6.5.1. Global Academic and Research Institute Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. CROs & CMOs
- 6.6.1. Global CROs & CMOs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Viral Capsid Development Market: Regional Estimates & Trend Analysis by Type, Application, & End Use.
- 7.1. Regional Dashboard
- 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
- 7.3. North America
- 7.3.1. North America Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Framework
- 7.3.2.4. U.S. Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Canada
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Framework
- 7.3.3.4. Canada Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Competitive Scenario
- 7.3.4.3. Regulatory Framework
- 7.3.4.4. Mexico Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Europe
- 7.4.1. Europe Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. UK
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. UK Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Germany
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Germany Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. France
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. France Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Italy
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Competitive Scenario
- 7.4.5.3. Regulatory Framework
- 7.4.5.4. Italy Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.6. Spain
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Competitive Scenario
- 7.4.6.3. Regulatory Framework
- 7.4.6.4. Spain Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Denmark
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Competitive Scenario
- 7.4.7.3. Regulatory Framework
- 7.4.7.4. Denmark Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.8. Sweden
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Competitive Scenario
- 7.4.8.3. Regulatory Framework
- 7.4.8.4. Sweden Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.9. Norway
- 7.4.9.1. Key Country Dynamics
- 7.4.9.2. Competitive Scenario
- 7.4.9.3. Regulatory Framework
- 7.4.9.4. Norway Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Asia Pacific Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. Japan
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Japan Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. China
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. China Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. India
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. India Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Australia
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Australia Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Thailand
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Thailand Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. South Korea
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. South Korea Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Latin America
- 7.6.1. Latin America Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Brazil Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Argentina Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. MEA
- 7.7.1. MEA Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. South Africa Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Saudi Arabia Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.4. UAE
- 7.7.4.1. Key Country Dynamics
- 7.7.4.2. Competitive Scenario
- 7.7.4.3. Regulatory Framework
- 7.7.4.4. UAE Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
- 7.7.5.1. Key Country Dynamics
- 7.7.5.2. Competitive Scenario
- 7.7.5.3. Regulatory Framework
- 7.7.5.4. Kuwait Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Share/ Position Analysis, 2025
- 8.4. Participant's Overview
- 8.4.1. PackGene Biotech Inc.
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Sartorius AG
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Revvity
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. VectorBuilder
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. AAVnerGene
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. AskBio Inc.
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Voyager Therapeutics
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Vigene Biosciences
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Capsigen
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. uniQure N.V.
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Strategic Initiatives
- 8.4.1. PackGene Biotech Inc.
